| Sep 6 |
NurExone Demonstrates Extended Therapeutic Window of ExoPTEN Post Spinal-Cord Injury in Preclinical Study
|
| Aug 28 |
NurExone Reports Second Quarter 2024 Financial Results and Provides Corporate Update
|
| Aug 23 |
NurExone Biologic Invited to Present Groundbreaking ExoPTEN Therapy at Prestigious September Conferences
|
| Aug 15 |
NurExone Biologic Achieves Key Milestone in Support of Robust Exosome Manufacturing Process
|
| Aug 9 |
NurExone's ExoPTEN, loaded with siRNA, Demonstrates Ability to Target Injury and Inflammation Sites – New Study
|
| Aug 1 |
NurExone Announces the Transfer of Manufacturing of the Active Element in ExoPTEN Drug to a Commercial GMP Manufacturer
|
| Jul 29 |
NurExone Announces Further Expansion of ExoPTEN Patent Coverage
|
| Jul 17 |
Promising Preliminary Results in Optic Nerve Recovery Study of NurExone’s first product ExoPTEN for Glaucoma
|
| Jul 17 |
Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now
|
| Jul 5 |
Updates from NurExone: Growth Conference Presentation and Website Relaunch
|
